Lipids

Valbiotis Announces the Completion of Recruitment for the Phase II HEART Clinical Study Conducted With TOTUM•070 in Hypercholesterolemia, a Risk Factor for Cardiovascular Disease

Retrieved on: 
Monday, September 6, 2021

In line with its development plan, Valbiotis confirms that the results of the HEART study will be available in the second quarter of 2022.

Key Points: 
  • In line with its development plan, Valbiotis confirms that the results of the HEART study will be available in the second quarter of 2022.
  • The HEART clinical study is a multicenter, international, randomized, placebo-controlled, double-blind study involving 120 people with untreated moderate hypercholesterolemia between 130 and 190 mg/dL.
  • The primary endpoint of the HEART study is the reduction of blood LDL-cholesterol levels, a risk factor for cardiovascular disease and in particular atherosclerosis, and it has several secondary objectives of interest.
  • The medical need is real: according to the WHO, nearly 40% of the world's adult population has high cholesterol, a well-known cardiovascular risk factor.

Maxxgroom Launches 'A True Game Changer' in Men's Grooming

Retrieved on: 
Tuesday, July 27, 2021

LAS VEGAS, July 27, 2021 /PRNewswire/ --Maxxgroom announced this week it has released the first-ever men's grooming ready-to-use wax stick called the MaxxGroom Wax Stick.

Key Points: 
  • LAS VEGAS, July 27, 2021 /PRNewswire/ --Maxxgroom announced this week it has released the first-ever men's grooming ready-to-use wax stick called the MaxxGroom Wax Stick.
  • "We all know that electric nose trimmers don't work well, are loud, annoying to use, and leave irritating thick stubble behind," said Brad Harrison, founder and owner of Maxxgroom Wax Sticks.
  • The Maxxgroom Wax Stick package includes four wax sticks and four post-wax swabs.
  • The swabs are made with organic jojoba oilwhich soothes the skin and removes any residue that has been left behind.

Generation Bio Announces Plan to Scale Next-Generation Rapid Enzymatic Manufacturing Process Across Portfolio and Provides Pipeline Update

Retrieved on: 
Wednesday, July 14, 2021

The company plans to continue partnering with contract manufacturing organizations during and after construction to ensure redundancy and secure additional ceDNA supply.

Key Points: 
  • The company plans to continue partnering with contract manufacturing organizations during and after construction to ensure redundancy and secure additional ceDNA supply.
  • As Generation Bio transitions to RES, it expects to update its program development strategy and timelines across its pipeline.
  • Generation Bio is currently advancing its liver-directed, cell-targeted lipid nanoparticle delivery system with RES for the lead hemophilia A program.
  • Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases.

Keio University Research: Demystifying the fatty-world of lipids

Retrieved on: 
Wednesday, July 14, 2021

The Keio Research Highlights website offers more details about this and other recent research being conducted by researchers at Keio University.

Key Points: 
  • The Keio Research Highlights website offers more details about this and other recent research being conducted by researchers at Keio University.
  • "The extremely diverse nature of lipids means that it is not only challenging to identify and determine species but also to quantify their roles as signaling molecules in physiology and disease," says Makoto Arita, a professor at the Keio University Faculty of Pharmacy.
  • They also identified unique lipid structures that are directly related to gut microorganisms, including acyl alpha-hydroxyl fatty acid (AAHFA).
  • "Ultimately, this research could potentially lead to the discovery of new functional metabolites involved in host homeostasis and the onset of diseases."

Keio University Research: Demystifying the fatty-world of lipids

Retrieved on: 
Wednesday, July 14, 2021

The Keio Research Highlights website offers more details about this and other recent research being conducted by researchers at Keio University.

Key Points: 
  • The Keio Research Highlights website offers more details about this and other recent research being conducted by researchers at Keio University.
  • "The extremely diverse nature of lipids means that it is not only challenging to identify and determine species but also to quantify their roles as signaling molecules in physiology and disease," says Makoto Arita, a professor at the Keio University Faculty of Pharmacy.
  • They also identified unique lipid structures that are directly related to gut microorganisms, including acyl alpha-hydroxyl fatty acid (AAHFA).
  • "Ultimately, this research could potentially lead to the discovery of new functional metabolites involved in host homeostasis and the onset of diseases."

eTheRNA immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreement

Retrieved on: 
Tuesday, July 13, 2021

NIEL and GHENT, Belgium, July 13, 2021 /PRNewswire/ --eTheRNA immunotherapies NV ('eTheRNA'), a clinical-stage company developing mRNA immunotherapies for the treatment of cancer and infectious diseases, announces a collaboration and license agreement with Ghent University.

Key Points: 
  • NIEL and GHENT, Belgium, July 13, 2021 /PRNewswire/ --eTheRNA immunotherapies NV ('eTheRNA'), a clinical-stage company developing mRNA immunotherapies for the treatment of cancer and infectious diseases, announces a collaboration and license agreement with Ghent University.
  • Steven Powell, CEO at eTheRNA immunotherapies commented: "We are delighted to collaborate with the laboratory of Prof. De Geest from Ghent University with their valuable, combined expertise in chemistry, nanotechnology and immunology.
  • This collaboration and license agreement gives us access to lipid nanoparticles with enhanced thermostability and improved safety profiles.
  • Prof. Bruno De Geest, Ghent University commented: "I am delighted that my long-lasting collaboration with Dr. Stefaan De Koker from eTheRNA immunotherapies has culminated in this successful technology platform.

eTheRNA immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreement

Retrieved on: 
Tuesday, July 13, 2021

NIEL and GHENT, Belgium, July 13, 2021 /PRNewswire/ --eTheRNA immunotherapies NV ('eTheRNA'), a clinical-stage company developing mRNA immunotherapies for the treatment of cancer and infectious diseases, announces a collaboration and license agreement with Ghent University.

Key Points: 
  • NIEL and GHENT, Belgium, July 13, 2021 /PRNewswire/ --eTheRNA immunotherapies NV ('eTheRNA'), a clinical-stage company developing mRNA immunotherapies for the treatment of cancer and infectious diseases, announces a collaboration and license agreement with Ghent University.
  • Steven Powell, CEO at eTheRNA immunotherapies commented: "We are delighted to collaborate with the laboratory of Prof. De Geest from Ghent University with their valuable, combined expertise in chemistry, nanotechnology and immunology.
  • This collaboration and license agreement gives us access to lipid nanoparticles with enhanced thermostability and improved safety profiles.
  • Prof. Bruno De Geest, Ghent University commented: "I am delighted that my long-lasting collaboration with Dr. Stefaan De Koker from eTheRNA immunotherapies has culminated in this successful technology platform.

Global Oleochemicals Markets 2021-2025: Fatty Acids, Fatty Alcohol, Glycerol, Fatty Amines - ResearchAndMarkets.com

Retrieved on: 
Monday, July 12, 2021

The report on oleochemicals market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

Key Points: 
  • The report on oleochemicals market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment.
  • The oleochemicals market analysis includes the product and application segments and geographic landscape.
  • This study identifies government initiatives regarding the use of oleochemicals as one of the prime reasons driving the oleochemicals market growth during the next few years.

Anthony P. Morise is being recognized by Continental Who's Who

Retrieved on: 
Friday, July 9, 2021

Va., July 9, 2021 /PRNewswire/ -- Anthony P. Morise is being recognized by Continental Who's Who as a Trusted Cardiologist for his exceptional work in the field of Lipidology and Cardiology and in recognition of his work at West Virginia University Heart and Vascular Institute.

Key Points: 
  • Va., July 9, 2021 /PRNewswire/ -- Anthony P. Morise is being recognized by Continental Who's Who as a Trusted Cardiologist for his exceptional work in the field of Lipidology and Cardiology and in recognition of his work at West Virginia University Heart and Vascular Institute.
  • Dr. Morise currently works for the West Virginia University Heart and Vascular Institute in Morgantown.
  • Dr. Morise is currently working on several clinical trials involving lipid disorders, and often sees and treats patients who have genetic lipid disorders.
  • Dr. Morise is board-certified in Internal Medicine and Cardiovascular Disease by the American Board of Internal Medicine (ABIM).

Novel 4D-Metabolomics and 4D-Lipidomics Workflows, Libraries and ML-based CCS Prediction Tools to Transform Metabolomics and Lipidomics

Retrieved on: 
Monday, June 21, 2021

Brukers collaborators are making major progress in 4D-Metabolomics by leveraging measured collision cross sections (CCS).

Key Points: 
  • Brukers collaborators are making major progress in 4D-Metabolomics by leveraging measured collision cross sections (CCS).
  • This allows CCS values to be utilized across the timsTOF community to increase confidence by reducing ambiguities - resulting in fewer false positive annotations.
  • Bruker also introduced CCS-Predict Pro, an optimized algorithm to predict CCS values across small molecule structures.
  • Dr. Lucy Woods, Bruker Business Unit Manager for Metabolomics & Lipidomics, commented: Our 4D-Lipidomics workflows utilizing CCS prediction with Kendrick Mass Defect analyses reduce ambiguity in lipid annotation.